Rosty Raykov Sells 2,431 Shares of Fennec Pharmaceuticals Inc (NASDAQ:FENC) Stock

Fennec Pharmaceuticals Inc (NASDAQ:FENC) Director Rosty Raykov sold 2,431 shares of the company’s stock in a transaction that occurred on Monday, November 4th. The shares were sold at an average price of $4.31, for a total transaction of $10,477.61. Following the completion of the transaction, the director now owns 66,432 shares of the company’s stock, valued at $286,321.92. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Rosty Raykov also recently made the following trade(s):

• On Tuesday, October 1st, Rosty Raykov sold 2,431 shares of Fennec Pharmaceuticals stock. The shares were sold at an average price of $4.94, for a total transaction of $12,009.14.

Fennec Pharmaceuticals Stock Performance

Shares of FENC opened at $4.80 on Wednesday. The stock has a market capitalization of $131.62 million, a price-to-earnings ratio of 120.00 and a beta of 0.27. Fennec Pharmaceuticals Inc has a 12 month low of $4.09 and a 12 month high of $11.92. The firm has a fifty day simple moving average of $4.90 and a 200 day simple moving average of $6.19. The company has a current ratio of 8.02, a quick ratio of 7.75 and a debt-to-equity ratio of 9.86.

Fennec Pharmaceuticals (NASDAQ:FENC) last posted its quarterly earnings data on Tuesday, August 13th. The company reported ($0.20) EPS for the quarter, missing analysts’ consensus estimates of $0.06 by ($0.26). The business had revenue of $7.26 million for the quarter, compared to analyst estimates of $13.67 million. Fennec Pharmaceuticals had a negative return on equity of 53.38% and a net margin of 5.59%. During the same quarter in the prior year, the company earned ($0.21) earnings per share. Research analysts forecast that Fennec Pharmaceuticals Inc will post 0.03 EPS for the current fiscal year.

Analyst Ratings Changes

FENC has been the subject of a number of research reports. HC Wainwright lowered their target price on Fennec Pharmaceuticals from $15.00 to $13.00 and set a “buy” rating for the company in a report on Thursday, August 22nd. Craig Hallum decreased their price objective on Fennec Pharmaceuticals from $17.00 to $15.00 and set a “buy” rating for the company in a report on Wednesday, August 14th. Finally, Wedbush reissued an “outperform” rating and issued a $14.00 target price (down previously from $16.00) on shares of Fennec Pharmaceuticals in a research report on Tuesday, August 13th.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the stock. Essex Investment Management Co. LLC acquired a new stake in shares of Fennec Pharmaceuticals in the 1st quarter valued at approximately $1,604,000. WINTON GROUP Ltd acquired a new stake in Fennec Pharmaceuticals in the second quarter valued at $409,000. Russell Investments Group Ltd. grew its position in shares of Fennec Pharmaceuticals by 71,275.0% in the 1st quarter. Russell Investments Group Ltd. now owns 34,260 shares of the company’s stock valued at $381,000 after acquiring an additional 34,212 shares during the period. Bank of New York Mellon Corp increased its stake in shares of Fennec Pharmaceuticals by 42.8% during the 2nd quarter. Bank of New York Mellon Corp now owns 68,724 shares of the company’s stock worth $420,000 after purchasing an additional 20,602 shares during the last quarter. Finally, Gendell Jeffrey L increased its stake in shares of Fennec Pharmaceuticals by 7.1% during the 1st quarter. Gendell Jeffrey L now owns 302,478 shares of the company’s stock worth $3,364,000 after purchasing an additional 20,000 shares during the last quarter. 55.51% of the stock is currently owned by institutional investors.

About Fennec Pharmaceuticals

Fennec Pharmaceuticals Inc, a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children.